Paychex's Growth Claims Face Scrutiny Amid Valuation Concerns

What happened

A Seeking Alpha article from April 2026 advocates for Paychex as a buy, citing Q3 2026 revenue growth of 19.9% YoY and a forward P/E of 15.9, which it claims represents a 36% discount to fair value. The article attributes this performance to accelerating organic growth post-Paycor acquisition and robust cross-selling, painting an optimistic picture of synergy capture. However, the DeepValue master report, based on 2025 SEC filings, maintains a HOLD rating due to a rich P/E of 24.36 and stock price over 41% above intrinsic value, with limited margin of safety. Critical risks highlighted in the report include Paycor integration uncertainties and headwinds from ERTC expiration, which could undermine near-term growth metrics. This divergence suggests the article may be overlooking fundamental challenges in favor of promotional optimism.

Implication

The article's assertion of a discount relies on a forward P/E that conflicts with DeepValue's current multiple, indicating potential timing or calculation discrepancies that warrant verification. DeepValue's overvaluation call implies limited upside unless earnings accelerate significantly to justify current prices, a scenario not yet confirmed in official filings. Paycor integration remains a key risk; any slippage in synergy realization could quickly erode the growth narrative and margin stability. Retention metrics, while improved, must be monitored against pre-pandemic baselines to ensure long-term client stickiness amid competitive pressures. Overall, a cautious stance is prudent until official 2026 results validate the article's claims and address the underlying risks.

Thesis delta

The article introduces new 2026 data suggesting stronger growth, which could shift the thesis towards a more bullish outlook if verified in upcoming filings. However, DeepValue's core concerns about overvaluation and integration risks remain unresolved, meaning the overall investment thesis retains a cautious hold unless further evidence emerges. Investors should await official Q3 2026 disclosures to reconcile these conflicting narratives before making decisions.